You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Protection of donor kidneys with synchronization modulation electric field (SMEF)
SBC: WR Biotech, LLC Topic: 400The objective of this proposal is to examine a novel technique called improved Synchronization Modulation Electric Field (i-SMEF) in protection of donor kidneys and improvement of transplanted graft functions. We will apply the i-SMEF on donor kidneys during cold storage and evaluate the transplanted graft function following kidney transplantation in mice.We have developed a novel technique, named ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Phospholipid antimetabolite lipid ether amines for topical treatment of chronic wounds and associated biofilms.
SBC: INTEGUMED LLC Topic: NIDDKABSTRACT Chronic wounds affect over 2.5 million patients in the US alone, lasting on average 12-13 months and recurring in 60-70% of patients. These occur primarily in lower extremities and vascular disease, diabetes, nephropathy, and metabolic dysfunction are prevalent co-morbidities. These wounds frequently harbor bacterial infections as mixed Gram-negative (e.g. P. aeruginosa, PA) and Gram-posi ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Use of polymer-peptide system to deliver cells for intervertebral disc regeneration
SBC: BioRestorative Therapies, Inc. Topic: NIAMSAbstract Low back pain affects millions of Americans and causes $100 billion socioeconomic loss annually. One of the prominent risk factors is intervertebral disc degeneration. Current treatments are palliative for relieving pain without restoring disc biology or biomechanics. Pain recurrence is common. Spinal fusion is popular, but it is limited by high failure rate (up to 30%) while predisposes ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
An AI-assisted screening platform within a multivariate framework for biomarkers of mild cognitive impairment due to Alzheimer's disease
SBC: ISCREEN 2 PREVENT, LLC. Topic: RPROJECT SUMMARY In the past decade, the rate of deaths from Alzheimerandapos;s disease (AD) and other dementias escalated more than twice the rate of deaths from heart disease. Unfortunately, there is a lack of low-cost and non-invasive diagnostic instruments to accurately identify individuals at risk of AD and ADRD. Advanced non-invasive imaging shows that retinal neurodegeneration and visual def ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
High-density optical tomography of cerebral blood flow and metabolism in small animals
SBC: BIOPTICS TECHNOLOGY LLC Topic: 105ABSTRACT Many clinical situations, including stroke, expose the brain to insufficient cerebral blood flow (CBF) that cannot maintain normal cerebral metabolic rate of oxygen consumption (CMRO2) requirements, thereby leading to cerebral ischemic/hypoxic stresses and neurological disorders. Effective interventions are dependent on the findings of CBF/CMRO2 improvement and eventually neural recovery. ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Analyzing the efficacy of MMP-13 inhibitors in the treatment of CIPN
SBC: Avantyx Pharmaceuticals, LLC Topic: 102Project Summary The goal of this project is to establish an effective drug candidate to treat chemotherapy-induced peripheral neuropathy (CIPN). The National Cancer Institute estimates that approximately 400,000 (or ~60-70%) of patients undergoing chemotherapy suffer from CIPN. These patients may need to terminate chemotherapy treatment if experiencing symptoms, such as numbness, pain, temperature ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
New Treatments for Glaucoma
SBC: GRANNUS THERAPEUTICS, INC. Topic: NEIAbstract Aggregation of mutated myocilin (MYOC), a protein found in the endoplasmic reticulum (ER) of trabecular meshwork (TM) cells, disrupts the outflow of aqueous humor from the eye, causing increase in intraocular pressure (IOP), progressive retinal ganglion cell (RGC) death, and degeneration of the optic nerve, leading to primary open-angle glaucoma (POAG), characterized by irreversible visio ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Modular Adaptive Virtual Reality Intervention for Clinical Substance use disorder (MAVRICS)
SBC: INNATEVR LLC Topic: NIDAPROJECT SUMMARY/ABSTRACT Opioid Use Disorder (OUD) is a chronic, recurring condition that if left untreated, poses a significant and ongoing public health threat. OUD is associated with significant impairments in physical and psychological health including increased mortality and high utilization of emergency medical care as well as increased risk of Hepatitis C and HIV infection and Neonatal Abst ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Development of Novel Therapeutic Molecules for Treatment of Squamous Head and Neck Cancers
SBC: Mekanistic Therapeutics, LLC Topic: 102Mekanistic Therapeutics seeks to design, discover, and develop anti-cancer agents that selectively inhibit multiple oncogenic pathways. Among Mekanistic’s portfolio are dual and highly selective inhibitors of EGFR and PI3 kinase, which were rationally designed to only target these two critical oncogenes. The PI3 kinase (PI3K)/AKT/mTOR pathway plays a central role in driving tumor cell survival a ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
A Peptide-Based Polyplex Platform for Nucleotides Delivery to the Sites of Inflammation
SBC: Trasir Therapeutics, Inc. Topic: 100AbstractRNA interference (RNAi) is an evolutionary conserved mechanism for post transcriptional control of protein expression in which short double-stranded RNA target specific messenger RNA (mRNA) for degradation, thus inhibiting protein translation. siRNA has great potential to revolutionize medicine by enabling highly specific and efficient silencing of proteins involved in disease pathogenesis ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health